Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

Company Overview

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways. In addition to these clinical-stage candidates, Sensei is advancing preclinical projects against novel innate immune checkpoints and exploring combination regimens to broaden therapeutic impact.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates across the United States and collaborates with academic and industry partners to accelerate research and development. The company’s leadership team brings extensive experience in antibody therapeutics, translational research and clinical development, supporting its mission to bring innovative immunotherapies through clinical trials and deliver new treatment options for patients worldwide.

Key Stats

• Today's Range: $11.49 to $12.00
• 50-Day Range: $7.21 to $11.53
• 52-Week Range: $5.00 to $17.40
• Volume: 6,746 shs
• Average Volume: 56,037 shs
• Market Capitalization: $14.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Moderate Buy

Sensei Biotherapeutics Stock Analysis - MarketRank™

Sensei Biotherapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 179th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Sensei Biotherapeutics has a consensus price target of $55.00, representing about 363.4% upside from its current price of $11.87.

Amount of Analyst Coverage

Sensei Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($1.17) to ($0.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sensei Biotherapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sensei Biotherapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sensei Biotherapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.26% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently increased by 0.97%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sensei Biotherapeutics does not currently pay a dividend.

Dividend Growth

Sensei Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.38

Percentage of Shares Shorted

1.26% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently increased by 0.97%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sensei Biotherapeutics this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.20% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.50% of the stock of Sensei Biotherapeutics is held by institutions.

SNSE Stock Analysis - Frequently Asked Questions

How have SNSE shares performed this year?

Sensei Biotherapeutics' stock was trading at $9.8020 on January 1st, 2025. Since then, SNSE stock has increased by 21.1% and is now trading at $11.87.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its earnings results on Tuesday, August, 5th. The company reported ($3.91) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.20) by $2.29.

When did Sensei Biotherapeutics' stock split?

Sensei Biotherapeutics shares reverse split before market open on Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Sensei Biotherapeutics IPO?

Sensei Biotherapeutics (SNSE) raised $100 million in an IPO on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. acted as the underwriters for the IPO.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sensei Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNSE
• CIK: 1829802
• Web: www.senseibio.com
• Phone: 240-243-8000
• Fax: N/A
• Employees: 40
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Sensei Biotherapeutics: $55.00
• High Price Target: $80.00
• Low Price Target: $30.00
• Potential Upside/Downside: +363.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($21.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -72.13%
• Return on Assets: -61.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.64
• Quick Ratio: 7.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $30.52 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 1,260,000
• Free Float: 968,000
• Market Cap: $14.96 million
• Optionable: Not Optionable
• Beta: 0.31